These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 26373275)
1. Path Forward for RAF Therapies: Inhibition of Monomers and Dimers. Kortum RL; Morrison DK Cancer Cell; 2015 Sep; 28(3):279-81. PubMed ID: 26373275 [TBL] [Abstract][Full Text] [Related]
2. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Yao Z; Torres NM; Tao A; Gao Y; Luo L; Li Q; de Stanchina E; Abdel-Wahab O; Solit DB; Poulikakos PI; Rosen N Cancer Cell; 2015 Sep; 28(3):370-83. PubMed ID: 26343582 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583 [TBL] [Abstract][Full Text] [Related]
4. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212 [TBL] [Abstract][Full Text] [Related]
5. Inhibitors of BRAF dimers using an allosteric site. Cotto-Rios XM; Agianian B; Gitego N; Zacharioudakis E; Giricz O; Wu Y; Zou Y; Verma A; Poulikakos PI; Gavathiotis E Nat Commun; 2020 Sep; 11(1):4370. PubMed ID: 32873792 [TBL] [Abstract][Full Text] [Related]
6. N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers. Grasso M; Estrada MA; Berrios KN; Winkler JD; Marmorstein R J Med Chem; 2018 Jun; 61(11):5034-5046. PubMed ID: 29727562 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Yaeger R; Yao Z; Hyman DM; Hechtman JF; Vakiani E; Zhao H; Su W; Wang L; Joelson A; Cercek A; Baselga J; de Stanchina E; Saltz L; Berger MF; Solit DB; Rosen N Cancer Res; 2017 Dec; 77(23):6513-6523. PubMed ID: 28951457 [No Abstract] [Full Text] [Related]
8. Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF. Gunderwala AY; Nimbvikar AA; Cope NJ; Li Z; Wang Z ACS Chem Biol; 2019 Jul; 14(7):1471-1480. PubMed ID: 31243962 [TBL] [Abstract][Full Text] [Related]
9. RAF inhibitors that evade paradoxical MAPK pathway activation. Zhang C; Spevak W; Zhang Y; Burton EA; Ma Y; Habets G; Zhang J; Lin J; Ewing T; Matusow B; Tsang G; Marimuthu A; Cho H; Wu G; Wang W; Fong D; Nguyen H; Shi S; Womack P; Nespi M; Shellooe R; Carias H; Powell B; Light E; Sanftner L; Walters J; Tsai J; West BL; Visor G; Rezaei H; Lin PS; Nolop K; Ibrahim PN; Hirth P; Bollag G Nature; 2015 Oct; 526(7574):583-6. PubMed ID: 26466569 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF Hong SP; Ahn SK Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859 [TBL] [Abstract][Full Text] [Related]
11. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Karoulia Z; Wu Y; Ahmed TA; Xin Q; Bollard J; Krepler C; Wu X; Zhang C; Bollag G; Herlyn M; Fagin JA; Lujambio A; Gavathiotis E; Poulikakos PI Cancer Cell; 2016 Sep; 30(3):485-498. PubMed ID: 27523909 [TBL] [Abstract][Full Text] [Related]
12. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. Tkacik E; Li K; Gonzalez-Del Pino G; Ha BH; Vinals J; Park E; Beyett TS; Eck MJ J Biol Chem; 2023 May; 299(5):104634. PubMed ID: 36963492 [TBL] [Abstract][Full Text] [Related]
13. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755 [TBL] [Abstract][Full Text] [Related]
15. Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling. Meador CB; Pao W Cancer Discov; 2015 Apr; 5(4):348-50. PubMed ID: 25847954 [TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360 [TBL] [Abstract][Full Text] [Related]
17. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of RAF dimers: it takes two to tango. Cook FA; Cook SJ Biochem Soc Trans; 2021 Feb; 49(1):237-251. PubMed ID: 33367512 [TBL] [Abstract][Full Text] [Related]
19. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210 [TBL] [Abstract][Full Text] [Related]
20. Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition. Allen A; Qin ACR; Raj N; Wang J; Uddin S; Yao Z; Tang L; Meyers PA; Taylor BS; Berger MF; Yaeger R; Reidy-Lagunes D; Pratilas CA PLoS One; 2019; 14(6):e0217399. PubMed ID: 31158244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]